Guidelines to document H. pylori antimicrobial resistance in the North America: Difference between revisions

Revision as of 19:39, 1 December 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Sargun Singh Walia M.B.B.S.[3]

Strong recommendation
1.Data regarding antibiotic resistance among H. pylori strains from North America remains scarce. Organized efforts are needed to document local, regional, and national patterns of resistance in order to guide the appropriate selection of H. pylori therapy

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{CMG}}; {{AE}} {{MKK}}, {{SSW}}
 ==2017 ACG Guidelines to document H. pylori antimicrobial resistance in the North America==
@@ Line 7: / Line 8: @@
 | colspan="1" style="text-align:center; background:LightGreen" |Strong recommendation
 |-
-| bgcolor="LightGreen" |1.Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10–14 days is a recommended fi rst-line treatment option.
+| bgcolor="LightGreen" |1.Data regarding antibiotic resistance among H. pylori strains from North America remains scarce. Organized efforts are needed to document local, regional,
-Bismuth quadruple therapy is particularly attractive in patients with any previous macrolide exposure or who are allergic to penicillin
+and national patterns of resistance in order to guide the appropriate selection of H. pylori therapy
-|-
-| bgcolor="LightGreen" |2.Concomitant therapy consisting of a PPI, clarithromycin, amoxicillin and a nitroimidazole for 10–14 days is a recommended first-line treatment option
 |-
 |}